The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Opens in a new tab or window The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced ...

The original rendition failed to mention the self-mixed/split regimen (in which the amounts of intermediate and short- or rapid-acting ... insulin mixed by the patient with a variable amount of ...

Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar ...

Medically reviewed by Danielle Weiss, MD When you have type 1 or type 2 diabetes, dangerous spikes in blood glucose (severe hyperglycemia) may mean you need to reduce blood sugar levels quickly. If ...

“Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar ...

as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first ...